Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 | Q9Y271 | 12/20 | 0.39 |
| ▸ | CYSLTR2 | Q9NS75 | 11/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.38 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.38 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.36 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6571774 | 0.92 | ALOX5AP (0.35) | CYSLTR1CYSLTR2ALOX5APTBXA2RGPBAR1 | |
| SCHEMBL4056757 | 0.92 | CYSLTR2 (0.37) | CYSLTR1CYSLTR2FFAR1AKR1B1ALOX5AP | |
| SCHEMBL4053392 | 0.85 | CYSLTR1 (0.39) | CYSLTR1CYSLTR2FFAR1AKR1B1ALOX5AP | |
| SCHEMBL5331476 | 0.84 | TBXA2R (0.42) | TBXA2R | |
| SCHEMBL5333781 | 0.82 | PDE10A (0.40) | CYSLTR1CYSLTR2ALOX5APGPBAR1 | |
| SCHEMBL4052136 | 0.82 | CYSLTR2 (0.36) | CYSLTR1CYSLTR2FFAR1AKR1B1ALOX5AP | |
| SCHEMBL4229150 | 0.81 | LTB4R (0.36) | CYSLTR1CYSLTR2ALOX5APTBXA2R | |
| SCHEMBL4051700 | 0.80 | CYSLTR2 (0.38) | CYSLTR1CYSLTR2FFAR1AKR1B1ALOX5AP | |
| SCHEMBL4688152 | 0.80 | CYSLTR2 (0.36) | CYSLTR1CYSLTR2FFAR1AKR1B1ALOX5AP | |
| SCHEMBL5337869 | 0.80 | CYSLTR1 (0.42) | CYSLTR1CYSLTR2TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040180884-A1 | Dibenzocycloheptene compound | UBE INDUSTRIES, LTD. (JP) | 2004-09-16 | — | — | US | claimed |
| EP-1408033-A1 | DIBENZOCYCLOHEPTENE COMPOUND | Ube Industries, Ltd. (JP) | 2004-04-14 | — | — | EP | claimed |
| US-7309718-B2 | Dibenzocycloheptene compound | UBE INDUSTRIES, LTD. (JP) | 2007-12-18 | — | — | US | disclosed |
| US-20040180884-A1 | Dibenzocycloheptene compound | UBE INDUSTRIES, LTD. (JP) | 2004-09-16 | — | — | US | disclosed |
| EP-1408033-A1 | DIBENZOCYCLOHEPTENE COMPOUND | Ube Industries, Ltd. (JP) | 2004-04-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180884-A1 | Dibenzocycloheptene compound | LTB4R2, LTA4H, LTC4S | CYSLTR1 6/4885CYSLTR2 5/4885FFAR1 305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.